BTLA, Mouse IgG2a Fc Fusion Protein

Référence B5001-61N-25ug

Conditionnement : 25ug

Marque : US Biological

Contactez votre distributeur local :


Téléphone : +1 850 650 7790


B5001-61N Rabbit Anti-BTLA, Mouse IgG2a Fc Fusion Protein (B- and T-lymphocyte Attenuator, B- and T-lymphocyte-associated Protein, BTLA1, CD272, FLJ16065, MGC129743)

Clone Type
Polyclonal
Grade
Purified
Applications
E
Shipping Temp
Blue Ice
Storage Temp
-20°C

Human CD272 (BTLA, B and T Lymphocyte Attenuator) is a member of the Immunoglobulin superfamily and has homology to CD152 (CTLA-4). Engagement of BTLA by its co receptor CD270 (HVEM, a TNF superfamily member) can down regulate activated T and B cell responses. BTLA levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines (1).||Reactivity:|CD272-muIg binds to recombinant HVEM-muIg.||Applications:|Suitable for use in ELISA. Other applications not tested.||Recommended Dilution:|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Purity: Purified by size exclusion.|Concentration: ~0.5mg/ml|Form: Supplied as liquid in 50mM sodium phosphate, pH 7.5, 100mM potassium chloride, 150mM sodium chloride. No preservative added.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as liquid in 50mM sodium phosphate, pH 7.5, 100mM potassium chloride, 150mM sodium chloride. No preservative added.
Purity
Purified by size exclusion.
References
1. Derre’ L, DE Speiser, et al. (2010) J Clin Invest 120(1):157-167, 2. Pasero C,D Olive, et al. (2009) Curr Mol Med 9 (7): 911-927, 3. Gavrieli M, KM Murphy, et al. (2006) Adv Immunol 92: 152-185.